Alle Fälle anzeigen
ORD 10064/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Kläger
- Sanofi SA (as successor of Sanofi Mature IP)
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Beklagte- Accord Healthcare S.L.U.
- Accord Healthcare GmbH (AT)
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
Vertreter: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason) - Division
- Munich LD
- Richter
- —
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 8. Mai 2025
Entscheidungen
- 2025-05-08Generic Order
The Munich Local Division judge-rapporteur issued a comprehensive interim conference order in the Sanofi pharmaceutical infringement proceedings against multiple generic manufacturers, covering the substitution of Sanofi Mature IP by Sanofi SA, interim questions of invalidity (including admissibility of counterclaims and late-filed arguments), and procedural scheduling. The order provided preliminary guidance on damages calculation methodology and noted that the EPO Board of Appeal outcome would be relevant to further steps.
Rechtsfragen:Interim conference guidance (R. 105 RoP)Validity of patent pending EPO Board of Appeal proceedingsCounterclaim for revocation admissibilityDamages calculation methodology in pharmaceutical proceedingsScheduling of oral hearing
Dokumente
- 69C3F0818AC6A18B54CA5F179BE77799_en.pdf2025-05-08EN